Drug Trial Radar · NCT06239467
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Feb 26, 2024
Primary completion
Dec 31, 2026
Study completion Aug 1, 2027
Sponsor
- Lead sponsor
- OnKure, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with fulvestrant (Part B), trastuzumab and tucatinib (Part C), atirmociclib (Part D), and ribociclib and fulvestrant (Part E). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal criteria are met.
Conditions
- Advanced Cancer
- Breast Cancer
- Advanced Solid Tumors
- PI3K Gene Mutation
Interventions
OKI-219Drug
Oral twice daily
FulvestrantDrug
Intramuscular injection
TrastuzumabDrug
Intravenous (IV)
TucatinibDrug
Oral twice daily
AtirmociclibDrug
Oral twice daily
RibociclibDrug
Oral once daily continuous for 21-days followed by 7 days off
Primary outcomes
What the sponsor says the trial is designed to measure.
- Identify maximum tolerated dose (MTD) of OKI-219 in monotherapyTime frame: Cycle 1 (First 28 days on treatment)
- Assess safety of OKI-219 as monotherapy or in combination with other anti-cancer therapies: incidence of SAEsTime frame: Through 30 days after last dose, an average of 1 year
- Assess safety of OKI-219 as monotherapy or in combination with other anti-cancer therapies: incidence of Grade 2 or greater treatment emergent adverse eventsTime frame: Through 30 days after last dose, an average of 1 year
- Assess rate of dose modifications during treatment with OKI-219 as monotherapy or in combination with other anti-cancer therapiesTime frame: Through last study dose, an average of 1 year
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
California Cancer Associates for Research and Excellence
Encinitas, California
University of California San Diego UCSD
La Jolla, California
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California
Hoag - Huntington Beach
Newport Beach, California
Regents of the University of Colorado
Aurora, Colorado
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
Massachusetts General Hospital
Boston, Massachusetts
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Stony Brook University
Stony Brook, New York
SCRI Oncology Partners - Nashville
Nashville, Tennessee
NEXT Oncology Virginia
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Institut Jules Bordet
Anderlecht, Belgium
UZ Leuven - Campus Gasthuisberg
Leuven, Belgium
GZA Hopsitals Campus Sint-Augustinus
Wilrijk, Belgium
Centre de Lutte Contre le Cancer CLCC - Centre Georges Francois Leclerc (CGFL)
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Centre Antoine Lacassagne
Nice, France
Hopital Lyon Sud
Pierre-Bénite, France
Institut Gustave Roussy
Villejuif, France
Ospedale San Raffaele
Milan, Italy
Ospedale San Gerardo-ASST Monza
Monza, Italy
Istituto Clinico Humanitas
Rozzano, Italy
Gachon University Gil Medical Center
Incheon, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
NEXT Oncology Phase I Unit / IOB- Hospital Quironsalud Barcelona
Barcelona, Spain
Hospital Beata Maria Ana
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
START - Madrid
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.